Clopidogrel News and Research

RSS
Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
Access to real-time genotype data influences prescriber behavior after PCI

Access to real-time genotype data influences prescriber behavior after PCI

Combination treatment lowers risk of ischemic stroke recurrence

Combination treatment lowers risk of ischemic stroke recurrence

Patients taking anti-depressants more likely to develop gastrointestinal bleeding

Patients taking anti-depressants more likely to develop gastrointestinal bleeding

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

Experimental vaccine shows promise to protect stroke survivors from blood clots

Experimental vaccine shows promise to protect stroke survivors from blood clots

Study aims to understand role of clopidogrel in patients with cardiovascular disease

Study aims to understand role of clopidogrel in patients with cardiovascular disease

Antiplatelet monotherapy appears to be safer but does not reduce risk of heart attack

Antiplatelet monotherapy appears to be safer but does not reduce risk of heart attack

Mono-antiplatelet therapy after aortic heart valve replacements may work as well as two drugs

Mono-antiplatelet therapy after aortic heart valve replacements may work as well as two drugs

Clot busting drug combo reduces risk of major strokes in high risk patients

Clot busting drug combo reduces risk of major strokes in high risk patients

Drug combination may prevent secondary stroke in certain patients, study shows

Drug combination may prevent secondary stroke in certain patients, study shows

Taking clot-preventing drug with aspirin may lower risk of major stroke, finds study

Taking clot-preventing drug with aspirin may lower risk of major stroke, finds study

Genetic testing could help guide blood-thinner treatment after stent placement

Genetic testing could help guide blood-thinner treatment after stent placement

Patients given six-month dual antiplatelet therapy have increased heart attack risk

Patients given six-month dual antiplatelet therapy have increased heart attack risk

Two anticlotting medicines better at reducing bleeding risk than triple therapy

Two anticlotting medicines better at reducing bleeding risk than triple therapy

New ESC Focused Update provides recommendations on DAPT in patients with coronary artery disease

New ESC Focused Update provides recommendations on DAPT in patients with coronary artery disease

Researchers develop new scoring method to predict bleeding risk after stroke

Researchers develop new scoring method to predict bleeding risk after stroke

Low-risk atrial fibrillation patients fare better without antithrombotic therapy, study finds

Low-risk atrial fibrillation patients fare better without antithrombotic therapy, study finds

Genetic testing at UMMC helps doctors identify effective medication for heart stent patients

Genetic testing at UMMC helps doctors identify effective medication for heart stent patients

Euro Heart Index 2016: France ranks 1st in heart care

Euro Heart Index 2016: France ranks 1st in heart care

New guidelines recommend use of antiplatelet therapy and exercise program for treatment of PAD

New guidelines recommend use of antiplatelet therapy and exercise program for treatment of PAD

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.